Breast Secretory Carcinoma — Variants & evidence

Breast Secretory Carcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

6 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–6 of 6 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NTRK3 Fusion6
(diagnostic)	Diagnostic	B	Supports Positive	3	submitted	EID10503 A 6-year-old female had invasive breast adenocarcinoma with the histopathologic features of a secretory breast carcinoma (SBC). FISH and RT-PCR on frozen tumor tissue found ETV6::NTRK3 fusion. 11 of … (full text at CIViC) PMID 12450792 · Tognon et al., 2002 · Open in CIViC	civic
〃	Diagnostic	B	Supports Positive	3	accepted	EID11343 In developing a FISH assay to detect ETV6::NTRK3 fusions, the authors found 3 of 4 secretary breast carcinomas were positive for the fusion. In a subsequent analysis of an invasive breast carcinoma t… (full text at CIViC) PMID 15101049 · Makretsov et al., 2004 · Open in CIViC	civic
〃	Diagnostic	B	Supports Positive	3	accepted	EID11344 12 of 13 (92%) secretory breast carcinomas were found to have ETV6::NTRK3 fusions by RT-PCR and/or FISH whereas other infiltrating ductal carcinomas were negative for the fusion. PMID 12450792 · Tognon et al., 2002 · Open in CIViC	civic
〃	Diagnostic	B	Supports Positive	3	accepted	EID11345 9 of 9 breast secretory carcinomas were found to have ETV6:NTRK3 fusions, a basal-like phenotype, and no additional pathogenic aberrations in genes commonly mutated in breast cancer. PMID 28548128 · Krings et al., 2017 · Open in CIViC	civic
(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	accepted	EID10504 A 6-year-old female was diagnosed with secretory breast carcinoma (SBC), a rare invasive breast adenocarcinoma. Analysis of the tumor revealed a genetic driver: an ETV6::NTRK3 gene fusion. This fusion… (full text at CIViC) PMID 12450792 · Tognon et al., 2002 · Open in CIViC	civic
Larotrectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID6475 Shukla et al report on a remarkable case study of a 14 year old pediatric patient with refractory secretory breast carcinoma first presenting as a fibroadenoma at 8 yo. Over the next years, she experi… (full text at CIViC) PMID 29623306 · Shukla et al., 2017 · Open in CIViC	civic

Data updated 14 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.